| |
Record |
Warning: mysql_fetch_field() expects parameter 2 to be long, string given in /home/arimmora/public_html/refbase/includes/include.inc.php on line 309
Links |
|
Author  |
Henderson, M.J.; Choi, S.; Beesley, A.H.; Sutton, R.; Venn, N.C.; Marshall, G.M.; Kees, U.R.; Haber, M.; Norris, M.D. |
|
| |
Title |
Mechanism of relapse in pediatric acute lymphoblastic leukemia |
Type |
Journal Article |
| |
Year |
2008 |
Publication |
Cell Cycle (Georgetown, Tex.) |
Abbreviated Journal |
Cell Cycle |
|
| |
Volume |
7 |
Issue |
10 |
Pages |
1315-1320 |
|
| |
Keywords |
Child; *Drug Resistance, Neoplasm; Gene Rearrangement/*genetics; Genetic Markers/genetics; Humans; Models, Biological; Polymerase Chain Reaction; Precursor Cell Lymphoblastic Leukemia-Lymphoma/*diagnosis/drug therapy/*prevention & control; Receptors, Antigen/genetics; Recurrence; Time Factors |
|
| |
Abstract |
Relapse following initial chemotherapy remains a barrier to survival in approximately 20% of children suffering from acute lymphoblastic leukemia (ALL). Recently, to investigate the mechanism of relapse, we analysed clonal populations in 27 pairs of matched diagnosis and relapse ALL samples using PCR-based detection of multiple antigen receptor gene rearrangements. These clonal markers revealed the emergence of apparently new populations at relapse in 13 patients. In those cases where the new 'relapse clone' could be detected in the diagnosis population, there was a close correlation between length of first remission and quantity of the relapse clone in the diagnosis sample. A shorter length of time to first relapse correlated with a higher quantity of the relapsing clone at diagnosis. This observation, together with demonstrated differential chemosensitivity between sub-clones at diagnosis, indicates that relapse in ALL patients may commonly involve selection of a minor intrinsically resistant sub-clone that is undetectable by routine PCR-based methods. From a clinical perspective, relapse prediction may be improved with strategies to detect minor potentially resistant sub-clones early during treatment, hence allowing intensification of therapy. Together with the availability of relevant in vivo experimental models and powerful technology for detailed analysis of patient specimens, this new information will help shape future experimentation towards targeted therapy for high-risk ALL. |
|
| |
Address |
Children's Cancer Institute Australiafor Medical Research, Experimental Therapeutics Program, PO Box 81 (HighSt), Randwick, Sydney, NSW 2031 Australia. mhenderson@ccia.unsw.edu.au |
|
| |
Corporate Author |
|
Thesis |
|
|
| |
Publisher |
|
Place of Publication |
|
Editor |
|
|
| |
Language |
English |
Summary Language |
|
Original Title |
|
|
| |
Series Editor |
|
Series Title |
|
Abbreviated Series Title |
|
|
| |
Series Volume |
|
Series Issue |
|
Edition |
|
|
| |
ISSN |
1551-4005 |
ISBN |
|
Medium |
|
|
| |
Area |
WP6 In vivo |
Expedition |
|
Conference |
|
|
| |
Notes |
PMID:18418081 |
Approved |
no |
|
| |
Call Number |
CBM.UAM @ ccobaleda @ |
Serial |
33 |
|
| Permanent link to this record |
